Becton, Dickinson and Company (NYSE:BDX) Stock Position Lifted by Rempart Asset Management Inc.

Rempart Asset Management Inc. lifted its stake in Becton, Dickinson and Company (NYSE:BDX) by 9.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 75,994 shares of the medical instruments supplier’s stock after buying an additional 6,342 shares during the period. Becton, Dickinson and Company makes up approximately 4.2% of Rempart Asset Management Inc.’s holdings, making the stock its 10th largest holding. Rempart Asset Management Inc.’s holdings in Becton, Dickinson and Company were worth $20,063,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Heritage Wealth Management LLC grew its stake in shares of Becton, Dickinson and Company by 152.4% in the fourth quarter. Heritage Wealth Management LLC now owns 106 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 64 shares during the last quarter. Tucker Asset Management LLC bought a new stake in shares of Becton, Dickinson and Company in the first quarter worth about $37,000. Advisors Asset Management Inc. bought a new stake in shares of Becton, Dickinson and Company in the first quarter worth about $40,000. Accel Wealth Management grew its stake in shares of Becton, Dickinson and Company by 254.0% in the first quarter. Accel Wealth Management now owns 177 shares of the medical instruments supplier’s stock worth $44,000 after purchasing an additional 127 shares during the last quarter. Finally, Grey Fox Wealth Advisors LLC bought a new stake in shares of Becton, Dickinson and Company in the fourth quarter worth about $47,000. Hedge funds and other institutional investors own 86.72% of the company’s stock.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,300 shares of the business’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $277.13, for a total transaction of $360,269.00. Following the completion of the sale, the executive vice president now directly owns 5,157 shares in the company, valued at approximately $1,429,159.41. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, EVP Michael David Garrison sold 1,300 shares of the business’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $277.13, for a total transaction of $360,269.00. Following the completion of the sale, the executive vice president now owns 5,157 shares of the company’s stock, valued at approximately $1,429,159.41. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP David Hickey sold 2,974 shares of the business’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $277.85, for a total transaction of $826,325.90. Following the sale, the executive vice president now directly owns 4,199 shares of the company’s stock, valued at approximately $1,166,692.15. The disclosure for this sale can be found here. In the last ninety days, insiders sold 5,581 shares of company stock worth $1,551,429. Insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.3 %

NYSE BDX traded down $0.88 during mid-day trading on Friday, reaching $263.74. The stock had a trading volume of 3,003,670 shares, compared to its average volume of 1,171,096. Becton, Dickinson and Company has a 1 year low of $215.90 and a 1 year high of $287.32. The stock has a market cap of $76.51 billion, a PE ratio of 47.87, a price-to-earnings-growth ratio of 2.20 and a beta of 0.57. The company has a fifty day moving average price of $272.46 and a 200 day moving average price of $257.92. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.25 and a quick ratio of 0.73.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.96 earnings per share for the quarter, topping analysts’ consensus estimates of $2.89 by $0.07. Becton, Dickinson and Company had a net margin of 8.73% and a return on equity of 13.24%. The company had revenue of $4.88 billion during the quarter, compared to analyst estimates of $4.84 billion. During the same period in the previous year, the business earned $2.66 EPS. The firm’s revenue for the quarter was up 5.1% on a year-over-year basis. On average, research analysts expect that Becton, Dickinson and Company will post 12.23 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be paid a dividend of $0.91 per share. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $3.64 dividend on an annualized basis and a yield of 1.38%. Becton, Dickinson and Company’s dividend payout ratio is presently 66.06%.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on BDX. Piper Sandler raised their target price on Becton, Dickinson and Company from $290.00 to $305.00 and gave the stock an “overweight” rating in a research note on Monday, July 24th. StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, August 16th. Raymond James cut their price objective on Becton, Dickinson and Company from $305.00 to $304.00 and set an “outperform” rating on the stock in a research report on Friday, August 4th. Citigroup lifted their price objective on Becton, Dickinson and Company from $260.00 to $282.00 and gave the company a “neutral” rating in a research report on Monday, August 21st. Finally, Morgan Stanley lifted their price objective on Becton, Dickinson and Company from $295.00 to $310.00 and gave the company an “overweight” rating in a research report on Friday, August 4th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $288.44.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.